Form 4: Akebia CCO Sells Shares for Tax Obligations

Akebia Therapeutics' Chief Commercial Officer, Nicholas Grund, sold 84,829 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Nicholas Grund, Chief Commercial Officer of Akebia Therapeutics, Inc. (AKBA), sold a total of 84,829 shares of common stock.
• The sales occurred on February 2, 2026, at a price of $1.39 per share.
• These transactions were executed automatically by the Issuer to cover tax withholding obligations.
• The sales were in connection with the vesting and settlement of restricted stock units granted on January 31, 2024 (53,585 shares) and January 31, 2025 (31,244 shares).
• The sales were made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Grund on September 9, 2025.
• Following these transactions, Mr. Grund beneficially owns 561,750 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine, pre-planned transaction to cover tax obligations associated with RSU vesting, not indicative of a change in company fundamentals or management's confidence.

Positives

• The sale was pre-planned under a Rule 10b5-1 trading plan, indicating a structured approach to managing equity.
• The sale was primarily to cover tax withholding obligations, which is a routine and expected event for RSU vesting.

Negatives

• An insider sale, even for tax purposes, reduces the direct ownership stake of a key executive.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that routine insider sales for tax withholding purposes, as disclosed in Form 4 filings, are common occurrences across all industries when restricted stock units or other equity awards vest. These transactions typically do not reflect a change in management's outlook on the company's prospects but rather a standard mechanism for managing equity compensation and tax liabilities.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned tax-related sale, not a discretionary sale signaling a change in confidence.
• Employees: No direct impact on employees beyond the reporting person.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned sale of shares by a Chief Commercial Officer to cover tax withholding obligations upon the vesting of restricted stock units. Such transactions are common and generally do not reflect a change in the company's fundamental outlook or the insider's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate as this event is neutral.

Keywords

Akebia Therapeutics, AKBA, Nicholas Grund, Chief Commercial Officer, CCO, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, 10b5-1 Plan